[1] BRIZEL D M, OVERGAARD J. Dose amifostine have a role in chemoradiation treatment-, 2003(6)
[2] ANNE P R, CURRAN W J Jr. A phase Ⅱ trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer, 2002(zk)
[3] CULY C R, SPENDER C M. Amifostine an update on its clinical status as a cytoprotectant in patients with cacer recieving chemotherapy on radiotherapy and its potential therapentic application in myelodysplastic syndrom. 2001(5). doi:10.2165/00003495-200161050-00012
[4] 黄平, 丁惠萍. 氨磷汀. 中国肿瘤2000(10)
[5] 高怡瑾. 化/放疗患者的细胞保护剂--氨磷汀, 2000(5)
[6] ACOSTA J C, RICHARD C, DELGADO M D. Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells, 2003(9)
[7] LEE E J, GERHOLD M, PALMER M W. P53 protein regulates the effects of amifostine on apoptosis,cell cycle progression,and cytoprotection, 2003(5)
[8] KATAOKA Y, MURLEY J S, KHODAREV N N. Activation of the nuclear transcription factor kappaB (NFkappaB) and differential gene expression in U87 glioma cells after exposure to the cytoprotector amifostine, 2002(1)
[9] GRDINA D J, MURLEY J S, KATAOKA Y E. Delationslips between cytoprotection and mutation prevention by WR-1065, 2002(92)
[10] KINTZEL P E. Anticancer drug-induced kiney disorders. 2001(1). doi:10.2165/00002018-200124010-00003
[11] 方志伟, 施学东, 魏广奇. 骨软组织恶性肿瘤患者大剂量顺铂、甲氨蝶呤化疗的肾损害, 1998(3)
[12] CHAUNCEY T R, GOOLEY T A, LIOID M E. Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell trasplantation. 2000(4)
[13] 崔慧娟, 张树军, 李佩文. 阿米福汀保护肾脏的疗效观察. 中华肿瘤杂志2002(1)
[14] LORUSSO D, FERRANDINA G, GREGGI S. Phase Ⅲ multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. 2003(7). doi:10.1093/annonc/mdg301
[15] 申戈, 鲍云华. 防治癌症病人化疗毒性的临床研究及临床前研究. 国外医学(药学分册)1999(6)
[16] NAZEYROLLAS P, FRANCES C, PREVOST A. Efficiency of amifostine as a protection against doxorubicin toxicity in rats during a 12-day treatment. 2003(1A)
[17] LLLIANO A, BARLETTA E, DEMARINO V. New triplet chemotherapy combination with carboplatin,paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung can-cer:a phase Ⅱ study. 2000(5C)
[18] IATROMANOLAKI A, SIVRIDIS E, MALTEZOS E. Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. 2002(zk). doi:10.1053/sonc.2002.37356
[19] LES F J, SHI G G, CORTES J E. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia. 2003(3). doi:10.1007/s00280-003-0654-4
[20] 杨莉, 耿保琴. 细胞保护剂氨磷汀. 实用肿瘤杂志2001(3). doi:10.3969/j.issn.1001-1692.2001.03.032
[21] MOORE D H, DONNELLY J, MCGUIRE W P. Limited access trial using amifostine for protection against cisplatin-and three-hour paclitaxel-induced neurotoxicity:a phase Ⅱ study of the Gynecologic Oncology Group. 2003(22). doi:10.1200/JCO.2003.02.086
[22] HAIGENTZM J R, KIM M, SORICH J. Sewa phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies. 2003(4). doi:10.1097/00001813-200304000-00010
[23] STANKIEWICZ A, SKRZYDLEWSKA E, MAKIELA M. Effects of amifostine on liver oxidative stress caused by cyclophosphamide administration to rats. 2002(2)
[24] BENNETT C L, LANE D, STINSON T. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer:preliminary results from a randomized phase Ⅱ clinical trial from Germany. 2001(2)
[25] KRUSE J J, STROOTMAN E G, WONDERGEM J. Effects of amifostine on radiation-induced cardiac damage. 2003(1). doi:10.1080/0891060310002168
[26] ZACKRISSON A L, MALMSTROM H, PERTERSON C. No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. 2002(2)
[27] VAN-DEN-BRANDE J, NANNAN-PANDAY V R, HOEKMAN K. Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine,and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors, 2001
[28] ANNE P R, CURRAN W J Jr. A phase Ⅱ trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer, 2002(zk) |
